PNU-99194A: A preferential dopamine D3 receptor antagonist

CNS Drug Reviews

Volumn 4, Issue 1, 1998, Pages 42-53

  Haadsma Svensson, Susanne R ^a   Svensson, Kjell A ^a  

^a PFIZER INC   (United States)

Author keywords

2 Aminoindan; Behavior; Dopamine D3; Neurochemistry; Rodent

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETYLCHOLINE; AMPHETAMINE; CLOZAPINE; DNA; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; HOMOVANILLIC ACID; INDAN DERIVATIVE; MESSENGER RNA; NAFADOTRIDE; PRAMIPEXOLE; QUINELORANE; RACLOPRIDE; REMOXIPRIDE; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; DRUG POTENTIATION; HUMAN; LOCOMOTION; NEUROCHEMISTRY; NONHUMAN; REINFORCEMENT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031659988     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1998.tb00040.x     Document Type: Review

References (56)

1. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996;93:1945-1949.
2. Arneric SP, Roetker A, Long JP. Potent anorexic-like effects of RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane) in the rat: a comparison with other dopamine-receptor agonists. Neuropharmacology 1982;21:885-890.
3. Arneric SP, Roetker A, Long JP, Mott J, Barfknecht CF. Effects of semirigid methoxamine analogs on vascular smooth muscle: Studies of methoxy-2-aminotetralin and 2-aminoindane derivatives. Arch Int Pharmacodyn 1982;257:263-273.
4. 3 dopamine antagonist PNU-99194A in rats: Comparison with psychomotor stimulants. Behav Pharmacol 1997;8(2&3):243-252.
5. Bartoszyk GD. Anxiolytic effects of dopamine receptor ligands. 1. Involvement of dopamine autoreceptors. Life Sci 1998;62:649-663.
6. Bhatnagar RK, Arneric SP, Cannon JG, Flynn J, Long JP. Structure activity relationships of presynaplic dopamine receptor agonists. Pharmacol Biochem Behav (Suppl 1) 1982;17:11-19.
7. 3 receptor-preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1997;283:794-799.
8. Caine SB, Koob GF. Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat. Behav Pharmacol 1995;6:333-347.
9. Cannon JG, Perez JA, Bhatnagar RK, Long JP, Sharabi FM. Conformationally restricted congeners of dopamine derived from 2-aminoindan. J Med Chem 1982;25:1442-1446.
10. 3 dopamine-receptor antagonists using an ethologically based approach. Psychopharmacology 1998;136:284-290.
11. 3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci 1994;6:1384-1387.
12. 3 receptor pharmacology. Dissertation from the Department of Pharmacology, Göteborg University, Göteborg, Sweden. 1996, ISBN: 91-628-1913-5.
13. 3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 1996;16:2020-2026.
14. 3 antagonist PNU-99194A. Psychopharmacology 1998 (in Press).
15. 3 receptor antagonist PNU-99194A on motor behavior and emotional reactivity in C57BL/6J mice. Eur J Pharmacol 1997;337:147-155.
16. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 1995;275:899-913.
17. 2 receptor. Clin Neuropharmacol (Suppl 1) 1995;18: S130-142.
18. 3 receptor: Opposite and synergistic interactions with cyclic AMP. J Neurochem 1997;68:1-9.
19. 3 receptor preference and improved pharmacokinetic properties. Bioorg Med Chem Lett 1994;4:689-694.
20. Hacksell U, Arvidsson L-E, Svensson U, et al. Monophenolic 2-(dipropylamino)indans and related compounds: Central dopamine receptor - stimulating activity. J Med Chem 1981;24:429-434.
21. 3 dopamine receptors. Soc Neurosci Abstr 1996:#693.8.
22. 3-preferring dopamine agonist. Soc Neurosci Abstr 1995:#448.14.
23. 3 receptors: Single neuron analysis on the ventral palladum. Soc Neurosci Abstr 1995:#448.13.
24. 3-receptor ligands on behavior and reward mechanisms. Dissertation from the Department of Pharmacology, Göteborg University, Göteborg, Sweden. 1994, ISBN: 91-628-1430-3.
25. 3-preferring compounds on conditioned place preference and intracranial self-stimulation in the rat. J Neural Trans Gen Sec 1995;101:27-39.
26. 3-preferring compounds in discrete areas of the rat brain. J Neural Trans Gen Sect 1995;102:209-220.
27. 3 receptor mutant mice. J Neurosci 1998;18:2231-2238.
28. Kujacic M. Dopaminergic control of adrenomedullary function in the rat. 1994, ISBN: 91-628-1435-4.
29. Kujacic M, Svensson K, Lofberg L, Carlsson A. Dopamine receptors, controlling dopamine levels in rat adrenal glands- comparison with central dopaminergic autoreceptors. J Neural Transm 1991;84:195-209.
30. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997;49:231-252.
31. 3 receptor antagonist, antagonizes brain energy metabolism evoked by the psychostimulant phencylidine (PCP): implications for antipsychotic therapy. Soc Neurosci Abstr 1997:#747.14.
32. 3 receptors. Cereb-Cortex 1996;6:561-570.
33. 2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 1995;275:885-989.
34. 3 receptor. Bioorg Med Chem Lett 1995;5:219-222.
35. 3 receptor. Bioorg Med Chem Lett 1996;6:403-408.
36. Nichols NF, Virden TB, Svensson KA. Effects of (+)-MK801 on locomotor activity and prepulse inhibition in rats: Comparison of potential antipsychotics between assays. Soc Neurosci Abstr 1997;391.17.
37. Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 1995;18: S34-S42.
38. 3-receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 1995;275:1239-1246.
39. 2 receptors. Psychopharmacology 1986;89: S32.
40. 3 receptor mRNA expression in the parietal and motor cortex in patients with schizophrenia. Proc Natl Acad Sci USA 1993;90:8942-8946.
41. Seeman P, VanTol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-270.
42. 1 dopaminergic activity of 7-OH-DPAT. Brain Res 1996;733:41-45.
43. 3) receptor as a target for neuroleptics. Nature 1990;347:146-151.
44. 3) as a novel target for antipsychotics. Biochem Pharmacol 1992;43:659-666.
45. Stable L. Do autoreceptors mediate dopamine agonist-induced yawning and suppression of locomotion? A critical review. Psychopharmacology 1992;106:1-13.
46. 3 dopamine receptor-deficient mouse: Evidence for reduced anxiety. Physiol Behav 1998;63:137-141.
47. 4 receptors as potential therapeutic targets. In: Jenner P and Demirdamar R, eds. Dopamine receptor subtypes: from basic science to clinic. Amsterdam: IOS Press, 1998:147-161.
48. 3 receptors. Neuropharmacology 1997;36:787-792.
49. 3 antagonists (+)-AJ76 and PNU-99194A on apomorphine-induced disruption of prepulse inhibition. Soc Neurosci Abstr 1997:#747.4.
50. 3-receptor antagonist, selectively abolishes amphetamine's non-striatal increases in brain energy metabolism: Implications for antipsychotic therapy. Soc Neurosci Abstr 1995:#341.15.
51. 3 receptor. Dissertation from the Department of Pharmacology, Göteborg University, Göteborg, Sweden. 1995, ISBN: 91-628-1529-6.
52. 3 receptor antagonists in regard to dopamine release, in vivo receptor displacement, and behavior. J Neural Transm 1994;98:39-55.
53. 3 receptor: A post-synaptic receptor inhibitory on rat Iocomotor activity. J Neural Transm 1993;94:11-19.
54. 3 agonist PD 128907 on brain dopamine synthesis in rat. J Neurochem 1997;69:2363-2368.
55. 3 ligands. Dimeric 2-(4-[3-aminopropoxy]phenyl)benzimidazole antagonists. Bioorg Med Chem Lett 1995;5:2541-2546.
56. 2 receptors. Neuron 1997;19:837-848.